Managing IP survey: SPC framework

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Managing IP survey: SPC framework

biotech168

Managing IP is seeking views from in-house counsel at pharma and biotech companies on the state of the SPC framework in Europe; including Article 3a, the waiver and unitary SPCs

biotech200

You can take the survey here. 

Please only take the survey if you are an in-house lawyer from a pharmaceutical, biotech or life sciences company.


We are looking to gain and share insight on how in-house IP counsel view the SPC framework in Europe; including Article 3a, the SPC Manufacturing Waiver and unitary SPCs. 

This is the second in our series of in-house surveys in 2019. You can read the special report on the findings of that survey, on the changing dynamic between artificial intelligence and IP, here.

Don’t miss the chance to have your say.

The survey should take no longer than five minutes to complete, and all responses will only be published in an aggregated and anonymised form. The more responses we get, the more illuminating the final report will be.

If you would like to discuss your thoughts in more detail, please contact Patrick Wingrove at patrick.wingrove@managingip.com

more from across site and SHARED ros bottom lb

More from across our site

The Unitary Patent has passed 100,000 registrations, but new data raises the question of whether 30% uptake is a ceiling or a staging post for further growth, say Michael Nielsen and Darren Smyth of EIP and Andrew Samm at Patently
The new generation of in-house IP leaders want commercial judgment, accessibility and flexibility, with AI raising expectations around both fees and delivery
The firm launched a San Diego office earlier this month, but California investment and expansion is far from complete
The industry’s response to AI requires an unfamiliar ingredient as firms battle to shape their futures
The firm is looking beyond replacing recently departed talent, betting instead on senior leaders to strengthen and expand its patent litigation platform
Olga Partington, director in Sterne Kessler’s biotechnology and chemical practice group, shares why a patent's vulnerability peaks when it is young, rather than when it is most valuable, under the PTAB's new framework
IP experts gathered in San Francisco last week to discuss the changing global SEP landscape and new licensing models for AI infrastructure
SKW Schwarz partner Daniel Kendziur explains how new green claims rules are changing his workload and bringing him into direct contact with marketing, PR and government affairs teams
The government is targeting earlier resolution of SEP disputes while ruling out a standalone IPEC rate determination track and restrictions on injunctions
Ana Castedo, who brings a strong focus on patent litigation, will help build the firm’s IP litigation offering in Madrid
Gift this article